November 22, 2024

• 

[THE INVESTOR] Shares of Samsung BioLogics rose 21.85 percent this year, becoming the biggest gainer among the large cap stocks on Korea’s main bourse KOSPI, according to Korea Exchange on May 1.

The contract drug manufacturing arm of Samsung saw the surge in the first four months this year, which compared to an average of 7.39 percent growth among pharmaceutical stocks. The KOSPI overall climbed 8.41 percent during the same period. 

Samsung BioLogics, which went public in November last year, was also the biggest gainer among the largest stocks in 17 other sectors, including Samsung Electronics, Hyundai Engineering & Construction and SK Telecom, which rose 18.48 percent, 17.76 percent and 11.38 percent, respectively.

The shares closed at 175,000 won (US$153) on April 30.

During the January-April period, Hanon Systems, the main machinery stock, was the biggest loser with a 16.7 percent plunge, followed by Hyundai Glovis, IS Dongseo and CJ Cheiljedang.

By Park Han-na (hnpark@heraldcorp.com)